Form 4: Larimar Therapeutics Director Acquires Stock Options

Frank E. Thomas, a director at Larimar Therapeutics, acquired 19,000 stock options on May 13, 2025, exercisable at $1.875.

Summary

• On May 13, 2025, Frank E. Thomas, a director of Larimar Therapeutics, Inc. [LRMR], acquired 19,000 stock options.
• The options have an exercise price of $1.875.
• The options vest on the earlier of May 13, 2026, or the date of the company's next annual meeting of stockholders, contingent upon continued service on the Board of Directors.
• Following the transaction, Thomas directly owns 19,000 derivative securities.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing related to stock option grants, so the sentiment is neutral.

Industry Context

This is a standard Form 4 filing, reflecting a change in beneficial ownership by a company insider. Such filings are common and provide transparency to the market regarding insider transactions.

Stakeholder Impact

• The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with those of the shareholders.

Key Dates

Keywords

stock options, Form 4, director, Larimar Therapeutics, LRMR, beneficial ownership, Frank E. Thomas